JCM
BMRN icon

Jafra Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jafra Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,000
Closed -$828K – 66
2016
Q4 		$828K Buy
+10,000
New +$860K 0.7% 50

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jafra Capital Management's BMRN Position: Q1 2017 in Review

Jafra Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2017, closing a stake of 10,000 shares — an estimated $828K sold.

Jafra Capital Management first reported a position in BMRN in Q4 2016 and held it in 1 quarter. The position peaked at $828K in Q4 2016. 418 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

  • Jafra Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Jafra Capital Management sold 10,000 BioMarin Pharmaceuticals shares in Q1 2017, an estimated $828K.
  • Jafra Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Jafra Capital Management's BioMarin Pharmaceuticals position peaked at $828K in Q4 2016.
  • 418 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on Jafra Capital Management's 13F filing for Q1 2017, filed 15 May 2017.